Hutchison China Meditech (HCM)- The
stock offers investors a strong
pipeline of differentiated candidates (up to 15 possible Breakthrough Therapy Designations), China exposure (via its
sales team of over 3,200 employees and 1,900 medical professionals), validating partnerships and several upcoming catalysts.
Besides being on the verge of profitability due to strong core
sales, Alkermes expects a number of
pipeline events in 2018 that could propel the
stock.